Cardiotoxicity Clinical Trials

25 recruiting

Cardiotoxicity Trials at a Glance

31 actively recruiting trials for cardiotoxicity are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Not Applicable with 12 trials, with the heaviest enrollment activity in New York, Madrid, and Detroit. Lead sponsors running cardiotoxicity studies include Ass. Prof. Jan Nyman, Dinesh Thavendiranathan, and Ain Shams University.

Browse cardiotoxicity trials by phase

Treatments under study

About Cardiotoxicity Clinical Trials

Looking for clinical trials for Cardiotoxicity? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiotoxicity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiotoxicity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting
Not Applicable

Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy

CardiotoxicityAnthracycline-induced Cardiotoxicity
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)93 enrolled1 locationNCT07528586
Recruiting
Phase 4

The STOP-MED CTRCD Trial

Heart FailureCancerCardiotoxicity+2 more
Dinesh Thavendiranathan335 enrolled14 locationsNCT06183437
Recruiting
Not Applicable

In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors

Cancer SurvivorsCardiotoxicityCardiovascular Toxicity Induced by Antitumoral Drugs
University College, London10 enrolled3 locationsNCT06778122
Recruiting

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Heart FailureBreast NeoplasmsCardiotoxicity+1 more
University Hospital, Caen600 enrolled1 locationNCT07191730
Recruiting
Not Applicable

Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age

Cardiotoxicity
IRCCS Azienda Ospedaliero-Universitaria di Bologna400 enrolled5 locationsNCT07382141
Recruiting
Not Applicable

Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study

Breast CancerHeart FailureCardiotoxicity+1 more
University of Alberta60 enrolled1 locationNCT06595147
Recruiting
Phase 2

A Study of Blood Pressure Control During Cancer Treatment

Breast CancerCardiotoxicity
Memorial Sloan Kettering Cancer Center130 enrolled7 locationsNCT06023576
Recruiting
Not Applicable

The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial

Heart FailureCancerCardiotoxicity
University Health Network, Toronto336 enrolled1 locationNCT05023785
Recruiting
Phase 3

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Cardiotoxicity
Maria Sklodowska-Curie National Research Institute of Oncology220 enrolled2 locationsNCT05271162
Recruiting
Phase 3

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7Cardiotoxicity+2 more
SWOG Cancer Research Network491 enrolled590 locationsNCT03418961
Recruiting
Phase 2

Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Breast CancerDoxorubicin Induced Cardiotoxicity
Tanta University46 enrolled1 locationNCT07137793
Recruiting

Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Immune Checkpoint Inhibitors, Cardiotoxicity
West China Second University Hospital22 enrolled1 locationNCT06132984
Recruiting
Not Applicable

Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer

HER2-positive Breast CancerCardiotoxicity
Odense University Hospital220 enrolled4 locationsNCT05406635
Recruiting
Not Applicable

Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)

CardiotoxicityCancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)Elderly+1 more
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514 enrolled14 locationsNCT03711110
Recruiting
Phase 4

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Breast CancerHeart FailureBreast Diseases+10 more
Silesian Centre for Heart Diseases600 enrolled4 locationsNCT05465031
Recruiting
Phase 3

Cardioprotection on Chemotherapy-Induced Cardiotoxicity

Cardiotoxicity
Ain Shams University30 enrolled2 locationsNCT06853951
Recruiting

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Heart FailureCardiotoxicityMyocardial Infarction+12 more
Peerbridge Health, Inc1,500 enrolled8 locationsNCT06699056
Recruiting

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

Heart FailureCardiotoxicityPediatric Cancer
Hari Narayan150 enrolled1 locationNCT04262830
Recruiting
Phase 1Phase 2

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Anthracycline Related Cardiotoxicity in Breast Cancer
Texas Tech University Health Sciences Center70 enrolled1 locationNCT03934905
Recruiting
Not Applicable

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

CardiotoxicityEndothelial DysfunctionAcute Myeloid Leukemia, Adult
Samara State Medical University100 enrolled1 locationNCT05703126